1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. ViroGates A/S
  6. News
  7. Summary
    VIRO   DK0061030574


Delayed Nasdaq Copenhagen  -  10:06 2022-06-29 am EDT
52.00 DKK    0.00%
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause 30-day mortality in all age groups.
06/20Invitation to ViroGates' investor meeting
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

ViroGates announces a current total of 33 clinical routine hospital customers and adjusts its disclosure policy

04/18/2022 | 06:20am EDT

COMPANY ANNOUNCEMENT - No. 09-2022 - 18 April 2022

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces a current total of 33 clinical routine hospital customers in nine markets.

During the creation of the Q1 2022 report, ViroGates’ sales representatives and distributors have reported a combined current total of 33 clinical routine hospital customers in nine markets. The number of routine customers is a significant increase from the +15 customers in six markets reported as of 31 December 2021 in the Annual Report of 2021. The primary reason for the rise is an increased awareness and interest in suPARnostic® following the EMA approval of suPAR-guided anakinra treatment in COVID-19 patients in December 2021.

The 33 customers are hospitals that have placed two or more orders of suPARnostic® products for clinical routine use in the last 12 months.

In the future, ViroGates will not make company announcements about small- to medium-sized individual hospital accounts because a single account is no longer considered insider information that can affect the share price, given the more extensive customer base. Future substantial individual accounts may still be considered insider information and will be announced individually.

To ensure transparency regarding customer development, ViroGates will report on the number of customers in more detail in future interim and annual reports.

Jakob Knudsen, CEO of ViroGates, says: ”We are delighted to see the rapid onboarding of many new hospitals across our key markets in the past few months. The new hospitals primarily use suPARnostic® for COVID-19 patients to assess the severity and prognosis of the disease. We do, however, also start to see the first hospitals transitioning from using suPARnostic® in COVID-19 to general emergency department triaging once they experience the value of suPAR as a biomarker. This transition is a focus area for us going forward.”

The announcement can be found at https://www.virogates.com/investor/announcements. 

For further information, please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. (+45) 2226 1355, email: jk@virogates.com

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers the Nordics, Spain, France and Benelux, while distributors serve other markets.

ViroGates' shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is a biomarker detected by ViroGates' suPARnostic® products. It is a protein found in the plasma. suPAR is considered a general risk status biomarker indicating inflammation and can indicate disease presence, severity, and progression across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 800 clinical trials and studies shows that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics' cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments and the Abbott Labs Architect™ and Alinity™ instruments. ViroGates works with partners to develop solutions for other platforms.

Disclosure regulation

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.


  • Jakob Knudsen, CEO, +45 2226 1355, jk@virogates.com


  • 20220418-Company Announcement 9.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases

All news about VIROGATES A/S
06/22ViroGates A/S Provides Revenue Guidance for the Year 2022 and 2023
06/21VIROGATES A/S : The nonspecific prognostic biomarker suPAR successfully predicts all-cause..
06/20Invitation to ViroGates' investor meeting
06/15ViroGates announces an offering of new shares with pre-emptive rights for existing shar..
06/15VIROGATES A/S : SuPAR as a Prognostic Marker of Ugandan Children at Risk of Severe and Fat..
05/30ViroGates announces the election of Patrik Dahlen as its new chairman of the board
05/30ViroGates A/S Announces Board Changes
05/25ViroGates announces the CE-IVD accreditation of its finger-prick blood-testing product,..
05/25ViroGates Announces the CE-Ivd Accreditation of Its Finger-Prick Blood-Testing Product,..
05/10VIROGATES : Healthy growth
More news
Sales 2021 7,66 M 1,08 M 1,08 M
Net income 2021 -17,7 M -2,49 M -2,49 M
Net cash 2021 14,9 M 2,09 M 2,09 M
P/E ratio 2021 -25,7x
Yield 2021 -
Capitalization 165 M 23,2 M 23,2 M
EV / Sales 2020 41,3x
EV / Sales 2021 57,6x
Nbr of Employees 14
Free-Float 52,3%
Duration : Period :
ViroGates A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIROGATES A/S
Short TermMid-TermLong Term
Income Statement Evolution
Managers and Directors
Jakob Knudsen Chief Executive Officer
Mark Christian Hvidberg da Silva Chief Financial Officer
Lars Kongsbak Chairman
Jesper Eugen-Olsen Chief Scientific Officer
Patrik Olof Dahlén Independent Director
Sector and Competitors